Axio BioPharma Expands Advisory Board with Patrick Haffey
Slice of Healthcare Team
06/23/2025
Key highlights
- Patrick Haffey joins advisory board, adding global GMP and scaling expertise
- Joins biotech leaders Dr. Greg Bleck and Dr. Graham Brearley
- Supports Axio's AI-enabled biologics manufacturing growth
- Haffey brings experience from Samsung Biologics, Jubilant Hollister-Stier
- Axio aims to accelerate biologics development and reduce production costs
Source: PR Newswire
Notable Quote
“ We're excited to welcome Pat to the advisory board alongside Greg and Graham. Together, they bring a tremendous depth of expertise in scaling biologics manufacturing and developing strategic partnerships. Their guidance will be invaluable as we expand our AI-enabled platform and grow our operational footprint. ”
Justin Byers, CEO at Axio BioPharma
Why This Matters
The addition of Patrick Haffey to Axio BioPharma’s advisory board signals the company’s strategic push to scale its AI-powered biologics manufacturing capabilities. With a leadership team now comprising seasoned experts in biologics development, regulatory strategy, and global GMP operations, Axio is well-positioned to drive innovation and efficiency in a sector under pressure to accelerate development timelines and reduce costs. These developments reinforce Axio’s commitment to reshaping biopharma production through advanced data-driven processes.
